(Q38994206)

8 September 2017

title

Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3. (English)

1 reference

8 September 2017

1 reference

Huan Ding

1

1 reference

8 September 2017

Ying Sun

series ordinal

2

1 reference

8 September 2017

Yu Hou

series ordinal

3

1 reference

8 September 2017

Li Li

series ordinal

4

1 reference

8 September 2017

publication date

16 May 2014

1 reference

8 September 2017

1 reference

8 September 2017

volume

32

1 reference

8 September 2017

issue

5

1 reference

8 September 2017

page(s)

720-726

1 reference

8 September 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Emerging molecularly targeted therapies in castration refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Current strategies in the management of hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Targeted therapy for advanced prostate cancer: Looking through new lenses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

INPP4B: the new kid on the PI3K block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Inositol polyphosphate 4-phosphatase B as a regulator of bone mass in mice and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Essential role for nuclear PTEN in maintaining chromosomal integrity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

The concept of synthetic lethality in the context of anticancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Discovery and validation of breast cancer subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Triple-negative breast cancer: therapeutic options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Basal-like breast cancer: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.11.012

10.1016/J.UROLONC.2013.11.012

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference